OTLK revenueFY2025$1.41M
- 10Y CAGR
- -12.2%
OTLK revenue was $1.41M for fiscal 2025 (ended Sep 30, 2025). Compound annual growth was -12.2% over 10 years.
Outlook Therapeutics Inc. (OTLK) financials
For fiscal 2025 (ended Sep 30, 2025), Outlook Therapeutics Inc. reported $1.41M of revenue and -$62.42M of net income.
- Revenue, FY2025
- $1.41M
- Net income, FY2025
- -$62.42M
- Net margin
- -4416.2%
- EPS, diluted, FY2025
- -$1.79
- Cash
- $11.24M
- P/S
- 75.90
- Market cap
- $107.3M
FY2016FY2025
FY2016FY2025
FY2016FY2019
OTLK revenue and earnings growth
OTLK net incomeQ3 2026-$20.32M
OTLK net income was -$20.32M in fiscal Q3 2026 (ended Jun 30, 2026), compared with -$20.15M a year earlier. For the full fiscal 2025 it was -$62.42M, compared with -$75.37M in fiscal 2024.
OTLK EPSQ3 2026-$0.15
OTLK diluted EPS was -$0.15 in fiscal Q3 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$1.79.
Income statement
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.41M | - | - | - | - | - | $8.15M | $3.09M | $3.81M | $2.98M |
| Cost of revenue | $1.36M | - | - | - | - | - | - | - | - | - |
| Gross profit | $57.2K | - | - | - | - | - | - | - | - | - |
| Research and development | $27.18M | $41.76M | $26.45M | $42.33M | $38.96M | $26.34M | $23.81M | $18.50M | $23.81M | $32.76M |
| Selling, general and admin | $39.94M | $29.94M | $26.67M | $20.74M | $12.77M | $9.97M | $9.37M | $14.23M | $15.88M | $21.56M |
| Operating income | -$67.06M | -$71.70M | -$53.13M | -$63.07M | -$51.73M | -$36.84M | -$36.30M | -$29.64M | -$35.88M | -$51.35M |
| Interest expense | - | $3.16M | $2.53M | - | - | $1.76M | $3.47M | $3.89M | $5.63M | $1.85M |
| Pre-tax income | -$63.98M | -$75.36M | -$58.98M | -$66.05M | -$53.16M | -$38.51M | -$37.93M | -$33.74M | -$38.35M | -$53.20M |
| Income tax | -$1.55M | $2.8K | $2.8K | $2.8K | $2.0K | -$3.27M | -$3.41M | -$3.65M | $501.5K | $103.0K |
| Net income | -$62.42M | -$75.37M | -$58.98M | -$66.05M | -$53.16M | -$35.24M | -$34.52M | -$30.09M | -$38.85M | -$53.30M |
| EPS, basic | -$1.79 | -$4.06 | -$4.72 | -$6.20 | -$7.00 | -$13.40 | -$39.60 | -$194.80 | -$33.40 | -$73.40 |
| EPS, diluted | -$1.79 | -$4.06 | -$4.72 | -$6.20 | -$7.00 | -$13.40 | -$39.60 | -$194.80 | -$36.00 | -$73.40 |
| Diluted shares | 34.8M | 18.5M | 12.5M | 10.6M | 7.6M | 3.6M | 909,591.35 | 246,610.1 | 1.2M | 860,649.15 |
Balance sheet
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.08M | $14.93M | $23.39M | $17.40M | $14.48M | $12.54M | $8.02M | $1.72M | $3.19M | $2.35M |
| Receivables | $1.49M | - | - | - | - | - | - | - | - | - |
| Inventory | $3.34M | - | - | - | - | - | - | - | - | - |
| Current assets | $17.39M | $27.42M | $30.98M | $27.52M | $21.51M | $17.94M | $13.50M | $3.30M | $3.90M | $5.68M |
| Total assets | $18.58M | $28.82M | $32.30M | $28.53M | $22.81M | $19.73M | $17.13M | $22.28M | $20.73M | $25.41M |
| Current liabilities | $45.81M | $42.55M | $46.73M | $19.73M | $6.75M | $15.89M | $20.29M | $32.04M | $28.74M | $20.44M |
| Short-term debt | - | - | - | - | - | - | $1.03B | $66.5K | $52.6K | $586.5K |
| Long-term debt | - | - | - | - | - | - | $50.28M | $98.5K | $151.1K | $2.23M |
| Total debt | - | - | - | - | - | - | $1.08B | $165.0K | $203.7K | $2.82M |
| Total liabilities | $50.77M | $101.90M | $46.74M | $19.79M | $18.20M | $16.91M | $27.90M | $43.09M | $51.46M | $30.58M |
| Shareholders' equity | -$32.19M | -$73.08M | -$14.44M | $8.74M | $4.61M | $2.83M | -$16.13M | -$25.54M | -$33.65M | -$5.17M |
Cash flow
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | -$54.25M | -$31.79M | -$32.29M | -$33.04M | -$15.51M | -$45.48M |
| Capital expenditures | - | - | - | - | - | - | $437.3K | $2.78M | $292.1K | $1.10M |
| Free cash flow | - | - | - | - | - | - | -$32.73M | -$35.82M | -$15.80M | -$46.58M |
| Investing cash flow | - | - | - | - | - | -$900.0K | -$437.3K | -$2.78M | -$292.1K | -$1.10M |
| Financing cash flow | $44.98M | $60.33M | $48.97M | $59.59M | $56.19M | $37.21M | $39.03M | $34.35M | $16.63M | $39.86M |
| Stock-based compensation | $8.90M | $5.39M | $5.55M | $7.71M | $4.89M | $2.81M | $1.31M | $1.99M | $8.57M | $12.45M |
| Depreciation and amortization | $117.1K | $113.9K | $44.2K | $204.7K | $262.1K | $554.1K | $3.36M | $3.05M | $2.69M | $2.39M |
Key ratios
| Line item | Sep 30, 2025 | Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | Sep 30, 2019 | Sep 30, 2018 | Sep 30, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | 163.8% | -19.0% | 27.9% | -42.9% |
| Gross margin | 4.0% | - | - | - | - | - | - | - | - | - |
| Operating margin | -4744.3% | - | - | - | - | - | -445.6% | -960.1% | -941.4% | -1723.3% |
| Net margin | -4416.2% | - | - | - | - | - | -423.8% | -974.6% | -1019.3% | -1788.9% |
| Free cash flow margin | - | - | - | - | - | - | -401.8% | -1160.2% | -414.5% | -1563.3% |
| Return on equity | - | - | - | -756.0% | -1153.9% | -1246.8% | - | - | - | - |
| Return on assets | -335.9% | -261.5% | -182.6% | -231.5% | -233.1% | -178.6% | -201.5% | -135.0% | -187.4% | -209.8% |
| Current ratio | 0.38 | 0.64 | 0.66 | 1.39 | 3.19 | 1.13 | 0.67 | 0.10 | 0.14 | 0.28 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $1.51M | - | - | - | - | - | - | - |
| Cost of revenue | $17.0K | $149.3K | $29.6K | $916.5K | $439.8K | - | - | - | - | - | - | - |
| Gross profit | -$8.3K | -$21.9K | -$1.24M | -$1.01M | $1.07M | - | - | - | - | - | - | - |
| Research and development | $3.25M | $4.50M | $3.63M | $5.98M | $7.13M | $4.41M | $9.66M | $12.52M | $11.20M | $13.51M | $4.53M | $4.94M |
| Selling, general and admin | $7.55M | $9.50M | $8.61M | $10.33M | $9.68M | $7.98M | $11.95M | $10.35M | $8.36M | $5.43M | $5.79M | $7.51M |
| Operating income | -$10.81M | -$14.03M | -$13.48M | -$17.31M | -$15.75M | -$12.39M | -$21.61M | -$22.88M | -$19.56M | -$18.94M | -$10.32M | -$12.46M |
| Interest expense | - | - | - | - | - | - | - | $0 | - | - | - | $206 |
| Pre-tax income | -$20.32M | -$4.45M | -$23.06M | -$14.85M | -$20.15M | -$46.35M | $17.38M | $5.69M | $44.41M | -$114.29M | -$11.18M | -$12.99M |
| Income tax | - | - | - | -$1.55M | $0 | $2.8K | $0 | $0 | $0 | $2.8K | $0 | $0 |
| Net income | -$20.32M | -$4.45M | -$23.06M | -$13.29M | -$20.15M | -$46.36M | $17.38M | $5.69M | $44.41M | -$114.29M | -$11.18M | -$12.99M |
| EPS, basic | -$0.15 | -$0.05 | -$0.38 | - | -$0.55 | -$1.50 | $0.72 | - | $1.91 | -$8.01 | -$0.86 | -$0.99 |
| EPS, diluted | -$0.15 | -$0.05 | -$0.38 | - | -$0.55 | -$1.50 | $0.72 | - | -$0.89 | -$8.01 | -$0.86 | -$0.99 |
| Diluted shares | 136.7M | 81.8M | 60.2M | - | 37.0M | 30.9M | 24.2M | - | 25.5M | 14.3M | 13.0M | - |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.24M | $7.75M | $8.68M | $8.08M | $8.90M | $7.56M | $5.70M | $14.93M | $32.02M | $47.23M | $10.36M | $23.39M |
| Receivables | $1.64M | $2.72M | $114.6K | $1.49M | $1.75M | - | - | - | - | - | - | - |
| Inventory | $5.04M | $3.34M | $3.46M | $3.34M | $4.13M | $3.60M | $3.11M | - | - | - | - | - |
| Current assets | $23.17M | $20.90M | $17.17M | $17.39M | $21.10M | $17.81M | $15.67M | $27.42M | $45.62M | $57.79M | $20.39M | $30.98M |
| Total assets | $26.18M | $21.89M | $18.24M | $18.58M | $22.39M | $19.08M | $17.01M | $28.82M | $47.09M | $59.03M | $21.68M | $32.30M |
| Current liabilities | $28.68M | $38.88M | $49.06M | $45.81M | $31.49M | $24.82M | $48.24M | $42.55M | $42.55M | $54.08M | $45.97M | $46.73M |
| Total liabilities | $36.58M | $50.89M | $56.79M | $50.77M | $59.58M | $51.54M | $67.30M | $101.90M | $130.77M | $193.26M | $46.03M | $46.74M |
| Shareholders' equity | -$10.39M | -$28.99M | -$38.55M | -$32.19M | -$37.19M | -$32.46M | -$50.29M | -$73.08M | -$83.67M | -$134.24M | -$24.34M | -$14.44M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.01M | -$7.83M | -$14.94M | -$12.38M | -$11.90M | -$16.58M | -$10.97M | -$16.98M | -$19.51M | -$19.27M | -$13.03M | -$12.74M |
| Financing cash flow | $26.60M | $6.90M | $15.53M | $11.56M | $13.25M | $18.44M | $1.74M | -$115.0K | $4.31M | $56.14M | -$3.2K | $2.42M |
| Stock-based compensation | $791.7K | $757.5K | $881.1K | $1.82M | $1.68M | $1.72M | $3.67M | $1.41M | $1.40M | $1.31M | $1.27M | $1.39M |
| Depreciation and amortization | $13.8K | $30.4K | $30.1K | $29.7K | $29.4K | $29.1K | $28.8K | $28.8K | $28.7K | $28.2K | $28.2K | $11.2K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | - | - | - | - | 70.8% | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -1046.2% | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | -1338.8% | - | - | - | - | - | - | - |
| Current ratio | 0.81 | 0.54 | 0.35 | 0.38 | 0.67 | 0.72 | 0.32 | 0.64 | 1.07 | 1.07 | 0.44 | 0.66 |
Source: XBRL data Outlook Therapeutics Inc. files with the SEC, latest filing dated Aug 18, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported May 15, 2024.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
OTLK peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| OTLK | $1.41M | - | -$62.42M | -4416.2% | $107.3M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
OTLK FAQ
7 questionsWhat is OTLK revenue?
Outlook Therapeutics Inc. (OTLK) reported $1.41M of revenue for fiscal 2025 (ended Sep 30, 2025).Is OTLK profitable?
No. Outlook Therapeutics Inc. reported a net loss of $62.42M for fiscal 2025 (ended Sep 30, 2025).How much cash and debt does OTLK have?
Outlook Therapeutics Inc. reported $11.24M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is OTLK gross margin?
Outlook Therapeutics Inc.'s gross profit was $57.2K on $1.41M of revenue for fiscal 2025 (ended Sep 30, 2025), a gross margin of 4.0%.What is OTLK earnings per share?
Diluted earnings per share were -$1.79 for fiscal 2025 (ended Sep 30, 2025), from SEC filings, restated for any stock split those filings show.When did OTLK last report financial results?
The latest statements here come from Outlook Therapeutics Inc.'s 10-Q filed on Aug 18, 2026, covering the period ended Jun 30, 2026.Where does this OTLK financial data come from?
Quantisnow builds these statements from the structured XBRL data Outlook Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.